This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Leveson, S. H. Articles by Goldrosen, M. H. Search for Related Content PubMed PubMed Citation Articles by Leveson, S. H. Articles by Goldrosen, M. H.

Correlations between the Leukocyte Adherence Inhibition Microassay and in Vivo Tests of Transplantation Resistance¹

Department of Surgery, St. James' Hospital, Leeds 9, England [S.H.L.], and Department of Surgical Oncology, Roswell Park Memorial Institute, Buffalo, New York 14263 [J.H.H., N.S.P., M.H.T., E.D.H., M.H.G.]

The leukocyte adherence inhibition (LAI) microassay detects tumor-associated antigen(s). Extracts of colon carcinoma (MCA-38 and B16 melanoma tumors, both syngeneic to the C57BL/6J mice) are recognized only by peritoneal cells from mice bearing the corresponding tumor. To ascertain whether this in vitro antigenic recognition correlates with the ability of the host to recognize and reject a tumor in vivo, serial LAI microassays were performed synchronously with experiments designed to test the ability of mice bearing tumors to reject live secondary tumor challenges.

Concomitant tumor immunity was present in the MCA-38 tumor-bearing mice on 3 occasions from 5 to 15 days from primary inoculation. In the B16 system, concomitant immunity was present on one occasion 10 days after primary inoculation. These results in turn were paralleled with the specific in vitro recognition of tumor antigens as detected by the LAI microassays. Loss of immunity in the "eclipse" phase of tumor development, as detected by concomitant tumor immunity, was paralleled by nonreactivity of the indicator cells in the LAI microassay.

¹ Presented at the International Workshop on Leukocyte Adherence Inhibition, May 15 to 17, 1978, Buffalo, N. Y. This work was supported in part by USPHS Grant CA 22931 from the Department of Surgical Oncology, Tumor Immunology Group, Roswell Park Memorial Institute, 666 Elm Street, Buffalo, N. Y. 14263.

² Presenter.

³ To whom requests for reprints should be addressed.